Skip to main content

Table 1 Baseline characteristics of PCOS women in the NAC group and control groups

From: N-acetylcysteine supplementation improves endocrine-metabolism profiles and ovulation induction efficacy in polycystic ovary syndrome

Characteristic

NAC group

n = 113

Control group

n = 112

p value

t or U value

/Z value

95% CI

/Risk ratio

(95% CI)

Effect size* (Cohen’s d/r/ φ/Cramér’s V)

Age (years)

28.50 (2.81)

28.02(2.99)

0.2092

1.259

-1.25-0.27

0.18

BMI (kg/m2)

23.36(20.70, 26.24)

24.17(22.04, 27.04)

0.1748

5665

-0.35-1.70

-0.09

Infertility duration (months)

12.00(6.00, 23.50)

12.00(6.00, 23.50)

0.6573

6113

-3.00-1.00

-0.03

Serum basal FSH (mIU/ml)

6.05(1.50)

5.79(1.63)

0.2284

1.208

-1.59-0.66

0.16

Serum basal LH(mIU/ml)

8.12(4.75, 12.08)

9.61(6.13, 13.79)

0.0724

5451

-0.12-2.69

-0.12

LH/FSH ratio

1.66(1.25, 2.45)

1.64(1.10, 2.41)

0.3366

5805

-0.33-0.12

-0.17

Serum basal E2(pg/ml)

33.71(26.00, 45.33)

35.35(26.00, 46.08)

0.4381

5841

-2.19-4.92

-0.05

Testosterone (ng/mL)

0.54(0.40, 0.78)

0.58(0.42, 0.84)

0.3098

5516

-0.04-0.11

-0.07

Prolactin (ng/ml)

13.89(10.96, 19.04)

13.19(10.45, 19.35)

0.4698

5186

-2.16-1.00

-0.05

The proportion of hyperprolactinemia (> 30 ng/ml) %(n)#

7.96% (9/113)

6.25% (7/112)

0.617

0.25

1.30(0.47–3.62)

0.02

AMH (ng/ml)

8.76(6.17, 11.76)

8.40(6.04, 11.13)

0.7751

6188

-1.13-0.86

-0.02

HOMA-IR

3.27(2.42, 4.73)

3.28(2.21, 4.83)

0.8925

6262

-0.47-0.40

-0.01

The proportion of women with insulin resistance (HOMA-IR > 2.69)

67.26% (76/113)

65.18% (73/112)

0.742

0.109

1.10(0.63–1.91)

0.01

Fasting insulin (mIU/L)

14.14(10.87, 20.58)

14.02(10.20, 21.00)

0.8633

6188

-1.87-1.57

-0.01

Fasting glucose (mmol/L)

5.20 (4.90, 5.50)

5.20 (4.90, 5.50)

0.7856

6195

-0.10-0.10

-0.02

Menses, %(n)

 Oligomenorrhoea

40.71% (46/113)

42.86% (48/112)

0.353

-0.062

-

0.004

 Amenorrhoea

7.08% (8/113)

10.71% (12/112)

 Irregular

41.59% (47/113)

41.07% (46/112)

 Regular

10.61% (12/113)

5.36% (6/112)

 Primary infertility, %(n)

80.53% (91/113)

75.89% (85/112)

0.399

0.71

1.31(0.70–2.48)

0.05

 Primiparity, %(n)

92.04% (104/113)

91.96% (103/112)

0.984

0

1.01(0.39–2.65)

0

  1. Data are presented as the means ± SDs, medians (25th and 75th percentiles) or percentages (numbers). Student’s t tests or Mann‒Whitney U tests were used for continuous variables, and chi-square tests were used for categorical variables
  2. NAC N-acetyl-L-cysteine, AMH anti-Mullerian hormone, HOMA-IR homeostasis model assessment insulin resistance index, FSH follicle-stimulating hormone, LH luteinizing hormone, E2 estradiol
  3. *Effect size measures the magnitude of the relationship or difference between groups. Cohen’s d was used for comparing means, r was for rank correlations, Phi(φ) was for 2 × 2 chi-square tests, and Cramér’s V is for larger contingency tables
  4. #All patients with hyperprolactinemia had already received medication and achieved normal serum prolactin levels before ovulation induction